6.03
Optinose Inc stock is traded at $6.03, with a volume of 2,672.
It is up +4.92% in the last 24 hours and down -4.92% over the past month.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
See More
Previous Close:
$5.89
Open:
$5.83
24h Volume:
2,672
Relative Volume:
0.04
Market Cap:
$59.23M
Revenue:
$75.67M
Net Income/Loss:
$-31.15M
P/E Ratio:
-21.71
EPS:
-0.2777
Net Cash Flow:
$-39.79M
1W Performance:
+3.00%
1M Performance:
-4.92%
6M Performance:
-58.18%
1Y Performance:
-66.23%
Optinose Inc Stock (OPTN) Company Profile
Name
Optinose Inc
Sector
Phone
267-364-3500
Address
777 TOWNSHIP LINE ROAD, YARDLEY, PA
Compare OPTN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OPTN
Optinose Inc
|
6.17 | 59.23M | 75.67M | -31.15M | -39.79M | -0.2777 |
![]()
ZTS
Zoetis Inc
|
174.15 | 77.71B | 9.15B | 2.43B | 2.31B | 5.32 |
![]()
HLN
Haleon Plc Adr
|
9.61 | 43.05B | 14.26B | 1.55B | 0 | 0.3383 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
13.38 | 42.23B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.46 | 19.33B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
NBIX
Neurocrine Biosciences Inc
|
152.49 | 15.26B | 2.24B | 385.90M | 440.10M | 3.73 |
Optinose Inc Stock (OPTN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-03-25 | Reiterated | H.C. Wainwright | Buy |
Mar-11-24 | Initiated | H.C. Wainwright | Buy |
Aug-21-23 | Initiated | Lake Street | Buy |
Oct-21-22 | Resumed | Jefferies | Buy |
Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
Dec-18-19 | Initiated | Cowen | Outperform |
Aug-08-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Optinose Inc Stock (OPTN) Latest News
OptiNose, Inc. (NASDAQ:OPTN) Sees Significant Decline in Short Interest - MarketBeat
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCE - MSN
OptiNose (STU:0OP0) Inventories, Raw Materials & Components : €2.05 Mil (As of Sep. 2024) - GuruFocus.com
OptiNose (FRA:0OP0) Earnings per Share (Diluted) : €-3.84 (TTM As of Sep. 2024) - GuruFocus.com
Lake Street Capital Issues Pessimistic Forecast for OptiNose (NASDAQ:OPTN) Stock Price - Defense World
OptiNose (NASDAQ:OPTN) Price Target Cut to $17.00 by Analysts at Lake Street Capital - MarketBeat
OptiNose (FRA:0OP0) Short-Term Capital Lease Obligation : €0.91 Mil (As of Sep. 2024) - GuruFocus.com
Optinose price target adjusted for stock split at Lake Street - Yahoo Finance
Optinose reports preliminary Q4 2024 XHANCE revenue - MSN
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million - GlobeNewswire
OPTNOptiNose, Inc. Latest Stock News & Market Updates - StockTitan
Midday Market Movers: Biggest Stock Declines of the Day – Market - HPBL
Optinose Reports Strong Q4: XHANCE Revenue Hits $22.4M with 20% Prescription Growth - StockTitan
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - GlobeNewswire Inc.
OptiNose (STU:0OP0) Profitability Rank : 3 (As of Sep. 2024) - GuruFocus.com
OptiNose (STU:0OP0) Change In Inventory : €-3.06 Mil (TTM As of Sep. 2024) - GuruFocus.com
OptiNose, Inc. (NASDAQ:OPTN) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
OptiNose (FRA:0OP0) Cyclically Adjusted Price-to-FCF : (As of Jan. 06, 2025) - GuruFocus.com
HC Wainwright Comments on OptiNose FY2029 Earnings - MarketBeat
HC Wainwright Forecasts OptiNose FY2029 Earnings - Defense World
Optinose price target adjusted for stock split at H.C. Wainwright - MSN
HC Wainwright Issues Positive Forecast for OptiNose (NASDAQ:OPTN) Stock Price - Defense World
Optinose stock price target raised at H.C. Wainwright given reverse split - Investing.com Canada
OptiNose (NASDAQ:OPTN) Shares Down 6.1%Time to Sell? - MarketBeat
OptiNose: Q1 Earnings Snapshot - Marketscreener.com
OptiNose, Inc. Announces Executive Appointments - Marketscreener.com
Optinose Announces Board Changes - Marketscreener.com
OptiNose stock hits 52-week high of $6.2 amid market fluctuations - Investing.com Nigeria
OptiNose stock hits 52-week high of $6.2 amid market fluctuations By Investing.com - Investing.com South Africa
Stock market news: Coeptis Therapeutics Holdings -96.03%, OptiNose -93.07% among biggest losers during mid day trading - Business Upturn
OptiNose (NASDAQ:OPTN) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Stock market today: Coeptis Therapeutics Holdings -95.79%, OptiNose -93.64% among biggest losers in early trading - Business Upturn
Optinose Announces 1-for-15 Reverse Stock Split - MSN
Optinose to effect 1-for-15 reverse stock split for Nasdaq compliance - MSN
OptiNose, Inc. (NASDAQ:OPTN) Sees Large Decline in Short Interest - MarketBeat
Yardley-Based Optinose Implements Reverse Stock Split to Boost Share Price, Avoid NASDAQ Delisting - BUCKSCO.Today
OptiNose Stock Scheduled to Reverse Split on Tuesday, December 31st (NASDAQ:OPTN) - Defense World
Optinose to enact 1-for-15 reverse stock split under threat of Nasdaq delisting - The Business Journals
Optinose announces reverse stock split to meet Nasdaq rules - Investing.com
Optinose (OPTN) Announces 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing Compliance - StockTitan
Optinose CEO Mahmoud Ramy A sells $2,030 in common stock By Investing.com - Investing.com South Africa
Optinose CEO Mahmoud Ramy A sells $2,030 in common stock - Investing.com India
Optinose chief legal officer sells shares worth $1,342 By Investing.com - Investing.com Australia
Optinose chief legal officer sells shares worth $1,342 - Investing.com
Optinose Inc Stock (OPTN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):